RenovoRx (NASDAQ:RNXT) CMO Ramtin Agah Acquires 50,000 Shares of Stock

RenovoRx, Inc. (NASDAQ:RNXT – Get Free Report) CMO Ramtin Agah purchased 50,000 shares of RenovoRx stock in a transaction dated Monday, November 16th. The stock was bought at an average price of $0.93 per share, with a total value of $46,500.00. Following the acquisition, the chief marketing officer directly owned 848,460 shares of the company’s stock, valued at approximately $789,067.80. This trade represents a 6.26% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

RenovoRx Price Performance

Shares of RNXT stock opened at $1.04 on Wednesday. The firm has a fifty day moving average of $1.40 and a 200-day moving average of $1.11. RenovoRx, Inc. has a 12-month low of $0.73 and a 12-month high of $2.59.

RenovoRx (NASDAQ:RNXT – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). The company had revenue of $1.07 million for the quarter, compared to analyst estimates of $1.06 million. RenovoRx had a negative return on equity of 133.49% and a negative net margin of 469.02%. Research analysts anticipate that RenovoRx, Inc. will post -0.28 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have issued reports on RNXT. Wall Street Zen downgraded RenovoRx from a “hold” rating to a “sell” rating in a research note on Monday, November 9th. Weiss Ratings raised RenovoRx from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, September 2nd. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $8.50.

Check Out Our Latest Stock Analysis on RNXT

Hedge Funds Weigh In On RenovoRx

Several hedge funds have recently made changes to their positions in RNXT. Cetera Investment Advisers lifted its position in shares of RenovoRx by 205.1% in the third quarter. Cetera Investment Advisers now owns 57,976 shares of the company’s stock worth $90,000 after purchasing an additional 38,976 shares in the last quarter. State Street Corp boosted its holdings in RenovoRx by 501.6% during the third quarter. State Street Corp now owns 314,636 shares of the company’s stock worth $491,000 after purchasing an additional 262,332 shares during the last quarter. Finally, T3 Companies LLC acquired a new position in RenovoRx during the third quarter worth $151,000. 3.10% of the stock is owned by institutional investors.

About RenovoRx

(Get Free Report)

RenovoRx, Inc. is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its approach is designed to deliver therapy directly to targeted tissue through the arteries that supply it, with the goal of limiting exposure to the rest of the body. The company’s platform includes RenovoCath, a catheter cleared by the U.S. Food and Drug Administration for the localized infusion of therapeutic agents. RenovoRx is also evaluating RenovoGem, a combination of its delivery approach and the chemotherapy drug gemcitabine, for patients with locally advanced pancreatic cancer.

Read More

Insider Buying and Selling by Quarter for RenovoRx (NASDAQ:RNXT)

Receive News & Ratings for RenovoRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RenovoRx and related companies with MarketBeat.com's FREE daily email newsletter.